N@N

AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2010 Financial Results, Webcast and Conference Call

^{Published on 2010-10-21 03:40:42 - Market Wire}
 

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the companya™s third quarter ended September 30, 2010 will be released before the market opens on Thursday, November 4, 2010. The AVEO management team will host a conference call discussing the companya™s financial results, recent developments and 2010 guidance on Thursday, November 4, 2010 at 10:00 a.m. (EDT). The call can be accessed by dialing 1-866-713-8563 (domestic) or 1-617-597-5311 (international) five minutes prior to the start of the call and providing the passcode 21275874. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 75499695. The replay will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the AVEO website at [ http://investor.aveopharma.com ]. A replay of the webcast will be archived on the companya™s website for two weeks following the call.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].